In this issue:
Outcomes of ASCT plus ibrutinibcontaining regimens
Is FL curable with standard chemoimmunotherapy?
Efficacy and safety of nilotinib plus Peg-IFN alfa-2a
LymphoVista and monitoring lymphoma
Efficacy of ipilimumab plus BV and nivolumab
Prognostic performance of MALT-IPI
Efficacy of zanubrutinib versus acalabrutinib plus venetoclax
Tolerability and efficacy of mosunetuzumab
Survival trends of advanced-stage MCL
Addressing treatment resistance and intolerance among CLL patients
Please login below to download this issue (PDF)